跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/CTRI/2013/10/004047
CTRI/2013/10/004047已完成未知

An Open-Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Single Dose, Crossover, Multicentre, Bioequivalence Study of Imatinib Mesylate Tablets 400 Mg of Cadila Healthcare Ltd., India and â??Gleevecâ?? (Imatinib Mesylate) Tablets 400 Mg of Novartis Pharmaceuticals Corporation, USA in Patients with Gastrointestinal Stromal Tumors or Chronic Myeloid Leukemia Under Fed Conditions.

Cadila Healthcare Ltd0 个研究点目标入组 38 人开始时间: 待定最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
未知
状态
已完成
入组人数
38
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Ba/be

入排标准

入选标准

  • •1)Patients must be receiving stable doses of Imatinib (i.e. 400 mg once a day) for the treatment of Gastrointestinal Stromal Tumors or Chronic Myeloid Leukemia.
  • •2)Males or non pregnant or non lactating females of age >= 18 years and <= 79 years.
  • •a)Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to initiation of the study & at the time of check-in of first period.
  • •b)Acceptable forms of contraception include the following:
  • •i.Intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
  • •ii.Barrier methods containing or used in conjunction with a spermicidal agent, or
  • •iii.Surgical sterilization, or
  • •iv.Practicing sexual abstinence throughout the course of the study
  • •c)Females will not be considered of childbearing potential if one of the following is reported and documented on the medical history:
  • •i.Postmenopausal with spontaneous amenorrhea for at least one year, or
  • •ii.Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or
  • •iii.Total hysterectomy and an absence of bleeding for at least 3 months
  • •3)Life expectancy of at least 3 months.
  • •4)Patients willing to not change their concurrent medications during the study.
  • •5)All patients should have a Body Mass Index (BMI) less than or equal to 30 but greater than or equal to 18. BMI values should be rounded to the nearest integer. (e.g. 30.4 rounds down to 30, while 17.5 rounds up to 18)
  • •6)Able to comply with Protocol requirements and assessments
  • •7)Able to give written informed consent to participate in the study
  • •8)All patients should be judged eligible by the principal investigator or co-investigator or physician during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include
  • •a)A complete medical history
  • •b)A normal or clinically non-significant physical examination.
  • •c)Within normal limits or clinically non-significant laboratory evaluation results (unless otherwise noted in the exclusion criteria)

排除标准

  • •Patients must not be enrolled in the study if they meet any one of the following criteria:
  • •1)History of allergic responses to Imatinib Mesylate, or other related drugs and any of its formulation ingredients.
  • •2)Patients receiving concomitant therapy of warfarin (coumarin anticoagulants) or history of usage of coumarin anticoagulants in the previous three months prior to study start (dosing).
  • •3)Consumption of grapefruit, grapefruit-like or grapefruit containing products within 7 days of drug administration.
  • •4)Ingestion of any alcoholic, caffeine or xanthine containing food or beverage within the 48 hours prior to the initial dose of study medication.
  • •5)Use of enzyme-modifying drugs within 30 days prior to receiving the first dose of study medication (listed in Appendix-II). They can be allowed depending on Principal Investigatorâ??s discretion in consultation with Medical monitor, if they are kept constant in the last 30 days and are expected to remain constant during the study period.
  • •6)Use of drugs metabolized by CYP3A4 and having a narrow therapeutic window like alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus or tacrolimus.
  • •7)History of moderate (30-50 ml/min creatinine clearance) or severe (<= 30 ml/min creatinine clearance) renal disease.
  • •8)Impaired hepatic function (bilirubin >=2 times the upper limit of normal, transaminases or alkaline phosphatase >= 2.5 times the upper limit of normal).
  • •9)Major surgery to the gastrointestinal tract, the liver or kidney within 4 weeks of study entry which may impact on the pharmacokinetics of Imatinib.
  • •10)Participation in any investigational drug study within 30 days prior to period 1 dosing.
  • •11)History of difficulty in swallowing, or any gastrointestinal disease which could affect drug absorption.
  • •12)Patients with cardiac disease or risk factors for cardiac failure.
  • •13)Patients with prior History of erythema multiforme or Stevens-Johnson syndrome
  • •14)Patients with History of Hypothyroidism or currently suffering from Hypothyroidism.
  • •15)Patients with History of Immunosuppression or in current Immunosuppression
  • •16)Patients with History of Tumor lysis syndrome
  • •17)Patients currently suffering from generalized edema and fluid retention (such as pleural effusion, pericardial effusion or ascites)
  • •18)Patients with prolonged QT or clinically significant ECG changes
  • •19)Donation or loss of blood or plasma of one unit (about 450 mL whole blood or 220 mL plasma) in the previous 60 days.
  • •20)Any significant disease or condition which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system, diabetes, psychosis or any other body system.
  • •21)History of drug dependence, history of alcoholism in the past 2 years prior to screening.
  • •22)Smokers, who smoke more than or equal to 10 cigarettes per day or more than or equal to
  • •20 biddies per day or those who cannot refrain from smoking during study period.
  • •23)History of difficulty with donating blood or difficulty in accessibility of veins or intolerance to venipuncture.
  • •24)History of allergic response to heparin.
  • •25)A positive hepatitis screen (includes subtypes B & C)
  • •26)A positive test result for HIV antibody and / or syphilis (RPR/VDRL)

研究者

相似试验

尚未招募
不适用
Compare and evaluate the bioavailability of Sunitinib Malate Capsules 50 mg of Oncogen Pharma (Malaysia) Sdn. Bhd. and â??SUTENT®â?? (Sunitinib Malate) Capsules 50 mg of Pfizer Labs in Subjects with Gastrointestinal Stromal Tumor or Advanced Renal Cell Carcinoma under Fasting Conditions.
CTRI/2021/06/034245Oncogen Pharma Malaysia Sdn Bhd
已完成
不适用
Pharmacokinetic Bioequivalence Study of Felbamate Tablet 600 mg in Adult Epilepsy Patients under Fasting Condition.
CTRI/2015/04/005681Cadila healthcare Ltd30
已完成
不适用
Bioequivalence Study Of Imatinib Mesylate Tablets 400 mg Of Cadila Healthcare Ltd., India And â??Gleevecâ?? (Imatinib Mesylate) Tablets 400 mg Of Novartis Pharmaceuticals Corporation, USA In Patients With Gastrointestinal Stromal Tumors Or Chronic Myeloid Leukemia Under Fed Conditions.
CTRI/2016/10/007398Cadila healthcare Ltd
招募中
不适用
A clinical trial intended to compare Bioequivalence of two formulations of Felbamate Suspension in Adult Epilepsy Patients under Fasting Conditions.
CTRI/2017/04/008429Vertice Pharma30
已完成
不适用
Pharmacokinetic study of two formulations of Azathioprine Tablets 50 mg in Adult Subjects with Rheumatoid Arthritis.
CTRI/2018/07/014995Alkem Laboratories Ltd64